Breast Health

Survival benefit in advanced or metastatic breast cancer with visceral metastases

June 12, 2020

Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.